Cornerstone Medical Associates, Inc.
$43.5K 311 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
OrphAI Therapeutics Inc.
OrphAI Therapeutics Inc. reported $43,669.50 across General Payments, Research, and Ownership to 5 physicians and teaching hospitals across 6 transactions.
- $43.7K
- All-tracks total
- 6
- Transactions
- 5
- Recipients
- −$1.1K
- General Payments vs PY2023
OrphAI Therapeutics Inc. reported $43,669.50 across all CMS Open Payments tracks (General + Research + Ownership) to 5 physicians and teaching hospitals in Program Year 2024 - ranking #1385 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $24,437.50, averaging $8.7K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer orphai-therapeutics-inc OrphAI Therapeutics Inc.
$43.7K · #1385/1,925 · 0.0% industry · PY2024
- TOT $43.7K
- RANK #1385
- SHARE 0.0%
- TXN 6
- RCP 5
- CAT 1
- GEN $24.4K
- ΔGEN −$1.1K
- TOP1 40.9%
- PY 2024
Volume peers
Nearest volume peer: Cornerstone Medical Associates, Inc. ($43.5K)
OrphAI Therapeutics Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
OrphAI Therapeutics Inc.'s CMS-reported General Payments decreased by $1.1K (−4.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ORPHAI THERAPEUTICS INC.PY2023: ORPHAI THERAPEUTICS INC.PY2024: OrphAI Therapeutics Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $25,562.50
- PY2024
- $24,437.50
What the Data Shows for OrphAI Therapeutics Inc.
OrphAI Therapeutics Inc. ranks #1385 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $43,669.50 across 6 transactions to 5 physicians and teaching hospitals - $7.3K per transaction and $8.7K per recipient on average.
Of the 1 general-payment categories charted below, "Consulting Fee" is the largest at $24.4K across 5 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 1 types of general payments, OrphAI Therapeutics Inc.'s largest category was "Consulting Fee" at $24.4K - 100.0% of General Payments.
How OrphAI Therapeutics Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $24.4K | 5 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $24,437.50 (100.0%) of $24,437.50 in this company's General Payments records across 3 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for OrphAI Therapeutics Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Stephen Strittmatter
$10,000.00 across 2 reported transactions
- 2
Langdon Miller
$9,687.50 across 2 reported transactions
- 3
Patrick Grohar
$4,750.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as OrphAI Therapeutics Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about OrphAI Therapeutics Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with OrphAI Therapeutics Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Valneva Usa, Inc.
$43.5K 67 recipients
Compare payment profiles
Oticon Medical, LLC
$43.5K 159 recipients
Compare payment profiles
TrackX Technology, Inc.
$44.2K 131 recipients
Compare payment profiles
Zap Surgical Systems, Inc.
$43.0K 105 recipients
Compare payment profiles
Whitehall International Inc
$44.4K 13 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.